Vertex Pharmaceuticals Incorporated

As of June 30, 2026, Vertex Pharmaceuticals Incorporated carries a market capitalization of 101.98B, placing it among publicly traded companies globally. Its enterprise value stands at 97.23B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Vertex Pharmaceuticals Incorporated's next confirmed earnings release is scheduled for November 2, 2026.

As of June 30, 2026, Vertex Pharmaceuticals Incorporated has 253.35M shares outstanding.

As of June 30, 2026, Vertex Pharmaceuticals Incorporated trades at a trailing price-to-earnings ratio of 28.77. The price-to-sales ratio is 10.07, and the price-to-book ratio stands at 6.23.

As of June 30, 2026, Vertex Pharmaceuticals Incorporated trades at an EV/EBITDA multiple of 24.08 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 9.56 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 25.20 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Vertex Pharmaceuticals Incorporated trades at an EV/FCF ratio of 31.66, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 97.23B versus a market cap of 101.98B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Vertex Pharmaceuticals Incorporated maintains a current ratio of 3.19, meaning it holds 3.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 9.77, indicating elevated leverage, while an interest coverage ratio of 757.45 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Vertex Pharmaceuticals Incorporated posted a return on equity (ROE) of 23.54, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 19.50 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 17.12, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 21.55, useful for judging operating efficiency across full business cycles. The company generates approximately 1.61M in revenue per employee across its workforce of 6,325.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.08 indicates how many times Vertex Pharmaceuticals Incorporated sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Vertex Pharmaceuticals Incorporated recorded 702.25M in income tax expense. That works out to an effective tax rate of 16.48, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 4.26B, leaving 3.56B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 19, 2026, Vertex Pharmaceuticals Incorporated's stock has gained approximately 34.54% over the past 52 weeks.

Over the twelve months ended June 30, 2026, Vertex Pharmaceuticals Incorporated generated 10.17B in revenue and converted that into 3.56B in net income, yielding earnings per share of 13.88. EBITDA reached 4.04B, while operating income came in at 3.86B.

As of June 30, 2026, Vertex Pharmaceuticals Incorporated holds 6.34B in cash and equivalents against 1.60B in total debt, resulting in a net debt position of -4.96B. Total book value stands at 16.36B, with working capital of 6.95B providing operational flexibility.

Vertex Pharmaceuticals Incorporated produced 3.47B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -401.33M in capital expenditures, free cash flow totaled 3.07B - equivalent to 12.06 per share.

Over the twelve months ended June 30, 2026, Vertex Pharmaceuticals Incorporated posted a gross margin of 86.00, reflecting its pricing power and cost economics. The operating margin of 37.95 and net profit margin of 35.00 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 2.97, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 1.74, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Vertex Pharmaceuticals Incorporated shareholders.

Vertex Pharmaceuticals Incorporated's most recent stock split took place on August 24, 2000 with a 1:2 split ratio.

As of June 30, 2026, Vertex Pharmaceuticals Incorporated has an Altman Z-Score of 12.90, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.